Lilly/Boehringer Ingelheim's insulin glargine product will be available in a pre-filled pen and cartridges for a reusable pen. The marketing authorisation for the Alliance's insulin glargine ...

By mode of administration, the injectable pens segment accounted for the highest revenue-grossing segment in the ... For ...

Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient in Sanofi’s Lantus blockbuster – have been dealt a blow. The FDA has issued a second ...

Original Medicare (Part A and Part B) does not cover insulin glargine (Basagalar ... acting insulin medication delivered through insulin pens called KwikPens. Basaglar is a brand-name drug ...

Objective — To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Research design and ...

vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin) pen fill ...